New neurology medication usage low due to high costs, similar effectiveness

Future studies are needed to determine if cost is a barrier for new medications with greater efficacy.

9:53 AM

Author | Noah Fromson

pills
Jacob Dwyer, Justine Ross, Michigan Medicine

While many new medications designed to treat neurologic diseases have hit the market, utilization by patients remains low due to high costs and similar effectiveness to existing drugs, a new study funded by the American Academy of Neurology finds.

A research team led by Michigan Medicine used pharmaceutical claims data from 2001 to 2019 to analyze use of new-to-market medications and existing guideline-supported medications for patients with one of 11 neurologic conditions, including multiple sclerosis, Parkinson's disease and migraine.

Results published in Neurology, the medical journal of AAN, reveal that fewer than 20% of patients were treated with new medications approved by the FDA between 2014 and 2018, while costs of these medications were significantly higher than existing treatments. The only condition with a higher usage rate of new medications was tardive dyskinesia at 32%.

The most expensive new treatment was edaravone for ALS at an average out-of-pocket cost of $713 a month. Researchers say the out-of-pocket costs for newer medications were more unpredictable than the costs for existing drugs due to the higher general costs of the medications and differences in each patient's insurance coverage.

"While some medications have shown a small increase in use, the overall impact of these new drugs is small, likely due to the comparable efficacy to the lower priced medications that were already on the market," said senior author Brian C. Callaghan, M.D., M.S., a neurologist at University of Michigan Health and the Eva L. Feldman, MD, PhD, Professor of Neurology at U-M Medical School. "Providers might also be deterred from prescribing these drugs due to high costs or insurance barriers. We must work to ensure that treatments for neurological conditions are affordable for patients."

Medications for two rare conditions, spinal muscular atrophy and transthyretin amyloidosis, have drastically improved outcomes. Researchers, however, were not able to analyze the effect of costs on use due to a limited number of participants.

View the release from the American Academy of Neurology.

Additional authors include Evan L. Reynolds, Ph.D., Gary Gallagher, M.D., Chloe E. Hill, M.D., Mousumi Banerjee, Ph.D., all of University of Michigan, Aristotle Mante, The American Academy of Neurology, and Gregory J. Esper, M.D., M.B.A., Emory University.

Disclosure: Callaghan consults for DynaMed, receives research support from the American Academy of Neurology and performs medical legal consultations including consultations for the Vaccine Injury Compensation Program.

Paper Cited: "Costs and Utilization of New-to-Market Neurologic Medications," Neurology. DOI: 10.1212/WNL.0000000000201627


More Articles About: Lab Notes Lou Gehrig's (ALS) Multiple Sclerosis (MS) Parkinson's Disease Medication Guidelines Drug Discovery Neurological (Brain) Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories
Health Lab
Father’s cancerous brain tumor found weeks after the birth of his daughter
Father’s cancerous brain tumor found weeks after the birth of his daughter
Person's hand holding an aspirin tablet with a glass of water nearby
Health Lab
An aspirin a day? Some older adults who take it may be following outdated advice
Many people aged 50 to 80 who said they take aspirin multiple times a week may not need to do so and could be causing health risks, according to National Poll on Healthy Aging.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
Patient lies in hospital bed after surgery with bandage on head, displays toys later after recovery
Health Lab
Lifechanging results for young woman after orange-sized brain tumor removed
Young woman thrives after surgery to remove a pilocytic astrocytoma tumor in her brain.
Three year old patient poses by Wonder Woman statue, wears costume
Health Lab
Three-year-old Wonder Woman making strides after customized spinal procedure
Three year old Wonder Woman fan thrives after customized minimally invasive selective dorsal rhizotomy to help symptoms of cerebral palsy and spastic diplegia
Illustration of neuron cell
Health Lab
Two genes linked to autism implicated in brain cell connectivity
A new study links two autism-associated genes together for the first time, potentially revealing a mechanism behind brain changes seen in people with autism.